Alamar Biosciences, Inc. (ALMR) Income Statement
ALMR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsALMR revenue and net income
Where ALMR's revenue goes
2025Each bar shows an amount and its share of revenue. ALMR kept −40.2% of revenue as net income.
ALMR profit margins
ALMR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +195.2% | — | — | — |
| Gross profit | +384.5% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ALMR quarterly EPS vs estimates
Alamar Biosciences beat the analyst EPS estimate in 1 of the last 1 quarters. Next report: November 3, 2026 (estimate $-0.22).
ALMR income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $74.2M | $25.1M |
| Cost of revenue | $32.5M | $16.5M |
| Gross profit | $41.7M | $8.6M |
| Research & development | $37.5M | $39.2M |
| Sales, general & admin | $35.6M | $18.9M |
| Total operating expenses | $73.0M | $74.7M |
| Operating income | −$31.3M | −$49.6M |
| Interest income | $2.2M | $4.7M |
| Interest expense | $401,000 | $2.1M |
| Income before taxes | −$29.2M | −$47.1M |
| Income taxes | $665,000 | — |
| Net income | −$29.8M | −$47.1M |
| EBITDA | −$24.9M | −$41.8M |
| Gross margin | 56.2% | 34.2% |
| Operating margin | −42.2% | −197.2% |
| Net margin | −40.2% | −187.2% |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $29.4M | $26.0M | $16.2M | $13.1M |
| Cost of revenue | $11.7M | $11.6M | $7.6M | $6.7M |
| Gross profit | $17.7M | $14.5M | $8.6M | $6.4M |
| Research & development | $13.8M | $13.0M | $8.9M | $8.3M |
| Sales, general & admin | $17.4M | $13.8M | $7.6M | $6.6M |
| Total operating expenses | $31.2M | $26.8M | $24.1M | $21.6M |
| Operating income | −$13.5M | −$12.3M | −$7.9M | −$8.6M |
| Interest income | $1.9M | $539,000 | $630,000 | $786,000 |
| Interest expense | $224,000 | $223,000 | $48,000 | $46,000 |
| Income before taxes | −$13.3M | −$20.9M | −$7.0M | −$7.7M |
| Income taxes | −$93,000 | $464,000 | — | — |
| Net income | −$13.2M | −$21.3M | −$7.0M | −$7.7M |
| EBITDA | −$11.9M | −$19.5M | −$6.1M | −$6.7M |
| EPS (diluted) | −$0.22 | −$1.74 | — | — |
| Gross margin | 60.2% | 55.5% | 53.1% | 48.8% |
| Operating margin | −46.0% | −47.4% | −49.0% | −65.3% |
| Net margin | −44.9% | −81.9% | −43.5% | −58.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ALMR's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ALMR financial results
In fiscal year 2025 (ended December 31, 2025), Alamar Biosciences reported revenue of $74.2 million, up 195.2% from the year before. It had a net loss of $29.8 million, a net profit margin of −40.2%.
See the ALMR stock overview for the latest quote and news, or the ALMR chart for price history and technical indicators.
ALMR income statement FAQ
What is Alamar Biosciences's annual revenue?
Alamar Biosciences reported total revenue of $74.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 195.2% from $25.1 million the previous year.
Is Alamar Biosciences profitable?
No. Alamar Biosciences reported a net loss of $29.8 million in fiscal 2025, a net profit margin of −40.2%; its operating margin was −42.2%.
What is Alamar Biosciences's gross margin?
Alamar Biosciences's gross margin was 56.2% in fiscal 2025: for every $100 of revenue, Alamar Biosciences kept $56 after the direct cost of its products and services.
How much does Alamar Biosciences spend on research and development?
Alamar Biosciences spent $37.5 million on research and development in fiscal 2025, 50.5% of revenue.
When will Alamar Biosciences report its next earnings?
Alamar Biosciences is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Alamar Biosciences's fiscal year end?
Alamar Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.